A study led by Shi et al. proposes a novel mechanism that links the regulation of a protein known as INHBA with macrophage polarization in the context of gastric cancer. This protein, governed by C/EBPβ transcription factor, is shown to play a pivotal role in transforming macrophages into a pro-tumorigenic M2 phenotype. The shift towards M2 polarization is particularly significant as these macrophages are known for their role in suppressing immune responses while promoting tissue repair and tumor progression.

The research underscores that INHBA is not merely a passive participant but a crucial player in orchestrating tumor immunity. Its induced M2 macrophage polarization influences multiple facets of tumor biology, including enhanced tumor growth and increased metastatic potential. One of the most critical aspects of the findings is the identification of the signaling pathways activated by INHBA. The study highlighted the PI3K/AKT pathway as a central player in mediating these effects, linking metabolic alterations to cellular responses that ultimately favor tumor survival.

Delving deeper into the molecular mechanisms, the activation of the PI3K/AKT pathway instigates a host of downstream effects that contribute to the tumor microenvironment’s permissiveness. This pathway is well-documented for its role in cellular growth, proliferation, and survival. When gastric cancer cells exploit this signaling circuit, it results in a robust survival advantage, particularly under stress conditions common within the tumor microenvironment, such as hypoxia and nutrient deficiency.

Furthermore, the interaction between gastric cancer cells and macrophages presents a complex landscape wherein both cellular types adapt their functions to support tumor progression. M2 macrophages, in particular, release a variety of cytokines and growth factors that can facilitate cancer cell survival, migration, and invasion. The research implies that targeting the INHBA-C/EBPβ axis could represent a promising therapeutic strategy to disrupt this symbiotic relationship and potentially reduce the aggressiveness of gastric cancer.

The findings of this study carry significant implications for developing novel therapeutic interventions. By targeting the pathways activated by INHBA or the resulting M2 macrophage polarization, it may be possible to improve the overall prognosis of gastric cancer patients. Additionally, understanding the precise role of the immune microenvironment in gastric cancer could lead to more effective immunotherapeutic approaches.

Immunotherapy, an exciting frontier in cancer treatment, has shown promise in various cancer types; however, gastric cancer has been historically resistant to these methods. The discovery that INHBA promotes immune evasion through macrophage transformation opens new avenues for combining traditional therapies with immune-modulating strategies. The overarching goal is to reinvigorate anti-tumor immune responses while simultaneously targeting malignant cells directly.

Moreover, the study emphasizes the importance of a comprehensive understanding of gastric cancer’s biology, which may vary vastly between patients. Personalized approaches that consider the unique immune landscapes and molecular signatures associated with each tumor will be essential for advancing treatment options in gastric cancer.

As the field of cancer research embraces personalized medicine, the spotlight on the interplay between tumor cells and the immune system will undoubtedly lead to transformative therapies. The ability to counteract the immune-suppressive tactics used by gastric cancer is imperative for enhancing treatment effectiveness and, ultimately, patient outcomes.

The authors of the study advocate for future research to further elucidate the pathways influenced by the INHBA-C/EBPβ axis and to explore their potential as biomarkers for gastric cancer progression and prognosis. The integration of this knowledge into clinical settings could revolutionize how healthcare professionals approach the treatment of gastric cancer.

In conclusion, the multifactorial nature of gastric cancer necessitates a concerted effort towards unraveling its complexities. Research that bridges the gap between tumor biology and immunology represents a crucial step towards developing innovative strategies that can shift the tide in favor of patient survival.

Understanding the mechanisms that bolster tumor growth and metastasis in gastric cancer, such as those involving INHBA and macrophage polarization, provides hope for the future. With continued focus and investment in this area, the medical community may transform gastric cancer from a once intractable problem into a manageable condition.

Subject of Research: The Role of INHBA in Macrophage Polarization and Tumor Progression in Gastric Cancer

Article Title: INHBA, regulated by C/EBPβ, induces M2 macrophage polarization to promote tumor metastasis and growth via activating the PI3K/AKT pathway in gastric cancer.

Article References:

Shi, DB., Qin, YC., Liu, S. et al. INHBA, regulated by C/EBPβ, induces M2 macrophage polarization to promote tumor metastasis and growth via activating the PI3K/AKT pathway in gastric cancer. Br J Cancer (2026). https://doi.org/10.1038/s41416-025-03326-5

Image Credits: AI Generated

DOI: 15 January 2026

Keywords: Gastric cancer, INHBA, M2 macrophage polarization, PI3K/AKT pathway, tumor growth, metastasis, immunotherapy, C/EBPβ.

Liver hepatocellular carcinoma is notorious for its aggressive nature and poor prognosis, primarily due to late diagnosis and limited effective treatment options. One of the hallmarks of aggressive cancers like LIHC is aerobic glycolysis—often referred to as the Warburg effect—where cancer cells preferentially generate energy through glycolysis even in the presence of adequate oxygen. This metabolic reprogramming supports rapid cancer cell proliferation and survival. However, the molecular regulators orchestrating this metabolic switch in LIHC remain incompletely understood.

The recent investigation sheds light on the role of RNA modifications in cancer metabolism, specifically focusing on 5-methylcytosine (m5C) modification, a chemical alteration of RNA that influences its stability and function. NSUN5, a member of the RNA m5C methyltransferase family, emerged as a key player. By analyzing expression data from The Cancer Genome Atlas (TCGA), the researchers discovered that both NSUN5 and EFNA3 are upregulated in LIHC and correlate strongly with poor patient survival, suggesting their contribution to tumor aggressiveness.

Mechanistically, NSUN5 was found to catalyze m5C methylation on the EFNA3 transcript. EFNA3, a gene encoding ephrin-A3, is implicated in various cellular processes including cell proliferation and migration, often hijacked during tumorigenesis. The m5C modification by NSUN5 stabilizes EFNA3 mRNA, enhancing its expression and facilitating enhanced glycolytic activity in tumor cells. This epigenetic modification essentially fuels the metabolic machinery that cancer cells rely on for growth and survival.

The research team employed a combination of in vitro and in vivo models to validate their findings. Knocking down NSUN5 in liver cancer cell lines resulted in a significant decrease in both cell viability and glycolytic activity, highlighting the enzyme’s critical role in maintaining the metabolic phenotype necessary for tumor progression. Interestingly, the suppression of NSUN5 also translated to slower tumor growth in animal xenograft models, reinforcing its tumourigenic importance.

Further molecular assays revealed a positive correlation between NSUN5 and EFNA3 expression. Notably, the overexpression of EFNA3 was able to rescue the inhibitory effects on glycolysis and cell viability caused by NSUN5 knockdown, underscoring that EFNA3 acts downstream of NSUN5’s epigenetic regulation. This finding confirms the NSUN5-m5C-EFNA3 axis as a critical pathway promoting LIHC progression.

Epitranscriptomics—the study of chemical modifications on RNA—has rapidly emerged as a frontier in understanding cancer biology. This study contributes significantly to that field by elucidating how m5C modification dynamically regulates gene expression relevant to tumor metabolism. Unlike genetic mutations, such epigenetic modifications offer a reversible means of regulating oncogenes and tumor suppressors, opening avenues for targeted therapy.

Importantly, the implication of NSUN5 in promoting glycolysis via m5C methylation of EFNA3 introduces a dual avenue for therapeutic exploitation. Targeting NSUN5 could disrupt the metabolic advantage tumor cells maintain, while simultaneously destabilizing oncogenic mRNA transcripts. Such strategies could potentially enhance the efficacy of existing treatments or lead to innovative drug designs aimed at the epitranscriptomic machinery.

Given that LIHC remains a leading cause of cancer-related mortality worldwide, largely due to limited therapeutic options, these findings inject fresh hope into the research and clinical communities. New therapeutic targets are urgently needed, especially those capable of halting cancer metabolism which fuels tumor growth and therapy resistance.

Furthermore, the findings of this study emphasize the importance of integrating RNA modification profiling in cancer diagnostics and treatment planning. Measuring NSUN5 and EFNA3 levels, alongside known biomarkers, could improve prognostic accuracy and help tailor personalized medical interventions for LIHC patients.

The study also raises intriguing questions about the broader roles of m5C modifications in other cancers and metabolic disorders. Whether NSUN5 influences other metabolic pathways or interacts with additional epigenetic regulators remain exciting topics for future research. Decoding the full spectrum of NSUN5’s targets could illuminate new principles of tumor biology.

While much work remains before these insights translate into clinical therapies, the study lays a robust foundation for drug development, including small molecule inhibitors or RNA-based therapeutics targeting the NSUN5-EFNA3 axis. Such agents could effectively ‘starve’ tumors of their glycolytic fuel source, crippling their growth capabilities.

Ultimately, this work exemplifies the power of multi-disciplinary research combining bioinformatics, molecular biology, and translational animal studies. As researchers continue to unpack the complex epigenetic networks in cancer, targeting RNA modification enzymes like NSUN5 holds considerable promise for more effective and less toxic cancer treatments.

In conclusion, the current study offers compelling evidence that NSUN5 serves as a key epitranscriptomic regulator in LIHC, accelerating tumor progression through m5C-mediated stabilization of EFNA3 and subsequent enhancement of glycolysis. These insights underscore the potential of NSUN5 as a valuable biomarker and a novel, actionable target to combat one of the most lethal cancers globally.

Subject of Research: Mechanisms by which the RNA methyltransferase NSUN5 influences glycolysis and tumor progression in liver hepatocellular carcinoma via m5C modification of EFNA3.

Article Title: NSUN5 accelerates the progression of liver hepatocellular carcinoma by m5C-EFNA3-mediated glycolysis

Article References:
Han, Y., Deng, X., Chen, H. et al. NSUN5 accelerates the progression of liver hepatocellular carcinoma by m5C-EFNA3-mediated glycolysis. BMC Cancer 25, 1237 (2025). https://doi.org/10.1186/s12885-025-14714-8

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14714-8